A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

ClinicalTrials.gov ID: NCT07226843

Public ClinicalTrials.gov record NCT07226843. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 14, 2026, 11:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

Study identification

NCT ID: NCT07226843
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 460 participants

Conditions and interventions

Conditions

Interventions

LY4584180 Drug
Rituximab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 16, 2026
Primary completion: Mar 31, 2027
Completion: Jan 31, 2030
Last update posted: Sep 7, 2026

2026 – 2030

United States locations

U.S. sites: 21
U.S. states: 14
U.S. cities: 19

Facility	City	State	ZIP	Site status
Mayo Clinic - Scottsdale	Scottsdale	Arizona	85259	Recruiting
City of Hope	Duarte	California	91010	Recruiting
University of California, Los Angeles (UCLA) - Medical Center	Los Angeles	California	90059	Recruiting
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center	San Francisco	California	94158	Not yet recruiting
Colorado Blood Cancer Institute	Denver	Colorado	80218	Recruiting
University of Miami - Sylvester Cancer Center	Miami	Florida	33136	Recruiting
Florida Cancer Specialists - Sarasota	Sarasota	Florida	34236	Recruiting
Emory University Hospital	Atlanta	Georgia	30322	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Mayo Clinic - Rochester	Rochester	Minnesota	55905	Recruiting
Columbia University	New York	New York	10032	Recruiting
University of Rochester	Rochester	New York	14618	Recruiting
The Ohio State University (OSU)	Columbus	Ohio	43210	Recruiting
Oregon Health & Science University (OHSU)	Portland	Oregon	97239	Not yet recruiting
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Recruiting
Vanderbilt University Medical Center	Nashville	Tennessee	37212	Recruiting
Texas Oncology - DFW (Sammons CC)	Dallas	Texas	75246	Recruiting
Baylor College of Medicine	Houston	Texas	77030	Not yet recruiting
University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance)	Seattle	Washington	98195	Recruiting
Froedtert Hospital and the Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07226843, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 7, 2026 · Synced Sep 14, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07226843 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →